Imatinib inhibits BCR-ABL tyrosine kinase activity and has been shown to effectively target the malignant clone in vitro and in vivo, resulting in a high percentage of long-term remissions in CML patients. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.